EXHIBIT 99.1
Shire Pharmaceuticals Group plc | ![]() |
4 February 2004
Shire Pharmaceuticals Group plc (the “Company”)
The Company announces that it was notified on 3 February 2004 under Sections 198 to 202 of the Companies Act that FMR Corp. and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries, both being non-beneficial holders, held solely for investment purposes in aggregate 58,308,058 ordinary shares of £0.05p each in the capital of the Company. These holdings represent 12.19 per cent of the issued ordinary share capital of the Company.
T May
Company Secretary
For further information please contact:
Investor Relations | |
Cléa Rosenfeld | +44 1256 894 160 |
Notes to editors
Shire Pharmaceuticals Group plc
Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently has a range of projects and products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.
For further information on Shire, please visit the Company’s website:www.shire.com